Halozyme Therapeutics, Inc. $HALO Shares Sold by GW&K Investment Management LLC

GW&K Investment Management LLC reduced its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 11.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,261,717 shares of the biopharmaceutical company’s stock after selling 162,799 shares during the period. Halozyme Therapeutics comprises 0.8% of GW&K Investment Management LLC’s holdings, making the stock its 18th largest position. GW&K Investment Management LLC owned about 1.07% of Halozyme Therapeutics worth $92,535,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the business. CWM LLC raised its position in Halozyme Therapeutics by 2,136.0% during the third quarter. CWM LLC now owns 23,881 shares of the biopharmaceutical company’s stock worth $1,751,000 after acquiring an additional 22,813 shares during the period. Arbor Investment Advisors LLC purchased a new position in Halozyme Therapeutics during the third quarter valued at $1,316,000. Monument Capital Management acquired a new stake in shares of Halozyme Therapeutics in the third quarter valued at about $2,015,000. Pacer Advisors Inc. increased its stake in shares of Halozyme Therapeutics by 2,054.7% during the third quarter. Pacer Advisors Inc. now owns 478,874 shares of the biopharmaceutical company’s stock worth $35,121,000 after purchasing an additional 456,649 shares in the last quarter. Finally, Cardinal Capital Management purchased a new stake in shares of Halozyme Therapeutics during the third quarter worth about $1,303,000. 97.79% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Halozyme Therapeutics

In other news, CEO Helen Torley sold 20,000 shares of the stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $76.12, for a total value of $1,522,400.00. Following the completion of the sale, the chief executive officer owned 708,719 shares of the company’s stock, valued at $53,947,690.28. This represents a 2.74% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Bernadette Connaughton sold 2,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $70.25, for a total transaction of $140,500.00. Following the sale, the director directly owned 40,123 shares in the company, valued at approximately $2,818,640.75. The trade was a 4.75% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 62,000 shares of company stock worth $4,545,200 over the last ninety days. 2.40% of the stock is owned by insiders.

Halozyme Therapeutics Stock Up 0.9%

Shares of NASDAQ:HALO opened at $70.02 on Thursday. The company has a quick ratio of 3.66, a current ratio of 4.66 and a debt-to-equity ratio of 43.89. The business has a fifty day moving average of $72.71 and a two-hundred day moving average of $70.76. The stock has a market cap of $8.26 billion, a P/E ratio of 28.12, a PEG ratio of 0.28 and a beta of 0.98. Halozyme Therapeutics, Inc. has a 52-week low of $47.50 and a 52-week high of $82.22.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing the consensus estimate of $1.92 by ($2.16). The company had revenue of $451.77 million for the quarter, compared to analysts’ expectations of $446.13 million. Halozyme Therapeutics had a return on equity of 136.12% and a net margin of 22.69%.The firm’s revenue was up 51.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.26 EPS. On average, research analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Wall Street Analysts Forecast Growth

HALO has been the topic of a number of research reports. Weiss Ratings lowered shares of Halozyme Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a research note on Tuesday, February 24th. Wall Street Zen cut Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Saturday, February 21st. HC Wainwright restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Thursday, January 29th. TD Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Wednesday, February 18th. Finally, The Goldman Sachs Group reissued a “sell” rating and issued a $56.00 price objective on shares of Halozyme Therapeutics in a research note on Thursday, December 4th. Six analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $78.56.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.